Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of nab-Paclitaxel plus Gemcitabine in Korean Patients with Metastatic and Advanced Pancreatic Ductal Adenocarcinoma
KCT0003564Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Jun 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, single-arm trial of nab-paclitaxel and gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Celgene Corporation. Started Jun 2015; status: completed.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on KCT0003564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003564.